2014•PubMedRequires access

[Recent advances in understanding reversion of multidrug resistance in hepatocellular carcinoma cells].

Yun‐Bo Shi, Min Yao, Dengfu Yao

Abstract

肝细胞肝癌(HCC)以手术治疗为主,辅之化学治疗、局部治疗等.早期肝癌可选择切除术及肝脏移植,但大部分患者就诊时已失去手术治疗机会[1].尽管新化学治疗药物与方案不断涌现,其效果仍不佳,原因是肝癌存在多药耐药(multidrug resistance,MDR).药物作用于癌细胞后,其胞内结构、信号通路与调控机制等改变,产生耐药,对药物敏感性降低甚至消失.MDR机制复杂,如细胞表面转运蛋白过表达、凋亡基因失调、酶活性改变等,致化学治疗失败.针对肝癌MDR的逆转方法较多,可降低肝癌MDR,增强化学治疗药物疗效.本文综述了肝癌MDR机制与逆转方法的研究进展. 关键词：癌,肝细胞;抗药性,多药;逆转方法

About this research paper

What this paper is about

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Reversion, Hepatocellular carcinoma, Multiple drug resistance, Cancer research, Biology, Drug resistance, Genetics, Phenotype